The Guardian view on vaccine justice: what the world needs now | Editorial

While some in the west are triple-dosed, the vast majority of health workers in Africa remain unprotected. Gestures won’t close the gulf

AstraZeneca’s halo has slipped. When it partnered with Oxford University, it promised to sell Covid vaccines at cost while the pandemic lasted; now it is signing its first for-profit deals, saying it believes that the illness is moving to an endemic phase. Even after more than 5m deaths, this is a highly questionable assertion. More than 250,000 new cases and 5,400 deaths were recorded globally on Monday.

But it would be wholly wrong to focus on AstraZeneca’s record when its rivals have been minting money while it maximised distribution. Pfizer says it will net $36bn this year from Covid vaccine sales. The problem is that shots are still not going where they are most needed. This is becoming a pandemic of poorer nations. More than 7bn doses have been distributed, but while more than two in 10 people over 12 in the UK have had a booster, fewer than one in 10 health workers in Africa have been fully vaccinated in the first place. This is, in the words of Dr Maria Kerkhove, the World Health Organization’s technical lead on Covid-19, outrageous. Our use of vaccines is too often inappropriate “epidemiologically, economically, ethically”, she said.

Pfizer says that by the year’s end, it will have shipped 1bn shots to low- and middle-income countries – but the more prosperous of these get the bulk of them. In correspondence with Amnesty International, it emerged that of 2bn doses sent by late September, only 15.4m had gone to the poorest nations. According to the research group Airfinity, approximately 84% of Johnson & Johnson’s vaccines and 96% of Moderna’s have gone to upper-middle- and high-income countries – though the latter is reportedly close to a deal to sell more doses to low- and middle-income countries after pressure from Joe Biden’s administration.

There are other signs of modest progress. Pfizer’s partner, BioNTech, is to build the first Covid vaccine manufacturing plants in Africa, in Rwanda and then Senegal. On Tuesday, Pfizer announced a deal allowing its new Covid treatment to be made and sold cheaply in 95 poorer countries. It follows a similar agreement made by Merck with 105 nations. The pills could be especially helpful in areas where people have trouble accessing hospitals.

But, as welcome as the agreement is, it excludes several key countries – notably Brazil, which has been racked by Covid – requiring them to buy direct from Pfizer. A treatment is no use unless people have easy access to reliable testing and healthcare. And, of course, it will not cut transmission as vaccines can.

Overall, we are seeing small, reputation-gilding advances in place of the giant leap needed to save lives. The EU and UK continue to block patent waivers for vaccines, and richer nations still grab more doses than they need. Britain threw away more than 600,000 AstraZeneca doses this summer after they expired and Oxfam believes at least 100m shots could expire unused in G7 countries by the end of the year, while others are given away so late that they cannot be distributed in time. While the WHO urged a moratorium on boosters, the UK will offer third shots to people as young as 40, and similar campaigns are under way elsewhere. Better use of mitigation measures, such as mandatory masking and vaccine passports, would have reduced the need for them.

As experts are now weary of pointing out, hoarding vaccines is not only immoral but foolish, increasing the risk of new and perhaps vaccine-resistant variants emerging as the virus circulates virtually unchecked in many places. Proper sharing of doses and of the information needed to make them is essential. What the world needs is not limited gestures, but large-scale, substantive and principled action.

Contributor

Editorial

The GuardianTramp

Related Content

Article image
The Guardian view on coronavirus and vaccine scepticism: time to act | Editorial
Editorial: Plans for mass immunisation against Covid-19 are developing fast, but concerns must be addressed

Editorial

22, Nov, 2020 @6:30 PM

Article image
The Guardian view on pandemic politics: we need cooperation, not confrontation | Editorial
Editorial: Vaccinating the world is the only way out of Covid but a mixture of nationalism and protectionism is blocking the exit

Editorial

22, Mar, 2021 @7:44 PM

Article image
The Guardian view on waiving Covid vaccine patents: protect the world, not big pharma | Editorial
Editorial: The US is now backing plans that could help billions more access vaccines. The UK should follow suit

Editorial

06, May, 2021 @6:14 PM

Article image
The Guardian view on the Covid vaccine breakthrough: making it work | Editorial
Editorial: At last, there is hope of an end to this pandemic. Scientists appear to have performed an amazing feat, the rest of us must do our best too

Editorial

10, Nov, 2020 @6:30 PM

Article image
The Guardian view on vaccine justice: the developing world won’t wait | Editorial
Editorial: Only one in four African healthcare workers is protected. Regional production and patent waivers are needed

Editorial

04, Feb, 2022 @6:30 PM

Article image
The Guardian view on vaccine nationalism: think again | Editorial
Editorial: The EU’s row with AstraZeneca is part of wider tensions over the distribution of doses

Editorial

28, Jan, 2021 @7:02 PM

Article image
The Guardian view on the vaccine rollout: the state we're in | Editorial
Editorial: Making mistakes, as Boris Johnson and the EU have discovered, is a precondition for ongoing success

Editorial

01, Feb, 2021 @6:47 PM

Article image
The Guardian view on the AstraZeneca vaccine: confidence from clarity | Editorial
Editorial: Where risk is involved, science deals in probabilities not certainties. Communication around vaccines must accept that reality

Editorial

07, Apr, 2021 @5:39 PM

Article image
Moderna, Pfizer or AstraZeneca? The ridiculous, diverting rise of vaccine envy
Casual vaccine chat is today’s only form of small talk, so it’s not surprising it would take a lightheartedly tribal turn. Ultimately, of course, gratitude is at the heart of the conversation

Zoe Williams

21, Jun, 2021 @6:00 AM

Article image
Change in vaccine policy is a high-stakes gamble | Letters
Letters: The effectiveness of delaying the second dose of Covid vaccines must be carefully monitored, argues Dr Grizelda George, while Jan Mortimer and Jenny van Tinteren fear the move will increase distrust and uncertainty

Letters

01, Jan, 2021 @5:31 PM